Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BLUW NASDAQ:IZTC NYSE:JATT NYSE:PLX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLUWBlue Water Acquisition Corp. III$10.32$10.27$9.93▼$10.41$290.20MN/A20,947 shs67,828 shsIZTCInvizyne Technologies$9.34-0.1%$9.76$8.50▼$23.00$58.39MN/A37,647 shs4,743 shsJATTJATT Acquisition$10.37-1.0%$9.10$9.99▼$11.31$83.18MN/A8,507 shs5,587 shsPLXProtalix BioTherapeutics$1.99-1.0%$2.11$1.32▼$3.19$160.34M-0.021.07 million shs565,755 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLUWBlue Water Acquisition Corp. III0.00%+0.49%+0.58%+0.10%+7.17%IZTCInvizyne Technologies-1.16%-3.81%-5.44%+27.85%-30.74%JATTJATT Acquisition-0.99%-1.38%-1.76%+48.71%+868.69%PLXProtalix BioTherapeutics-1.00%-5.69%-1.49%-24.05%+24.38%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLUWBlue Water Acquisition Corp. III$10.32$10.27$9.93▼$10.41$290.20MN/A20,947 shs67,828 shsIZTCInvizyne Technologies$9.34-0.1%$9.76$8.50▼$23.00$58.39MN/A37,647 shs4,743 shsJATTJATT Acquisition$10.37-1.0%$9.10$9.99▼$11.31$83.18MN/A8,507 shs5,587 shsPLXProtalix BioTherapeutics$1.99-1.0%$2.11$1.32▼$3.19$160.34M-0.021.07 million shs565,755 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLUWBlue Water Acquisition Corp. III0.00%+0.49%+0.58%+0.10%+7.17%IZTCInvizyne Technologies-1.16%-3.81%-5.44%+27.85%-30.74%JATTJATT Acquisition-0.99%-1.38%-1.76%+48.71%+868.69%PLXProtalix BioTherapeutics-1.00%-5.69%-1.49%-24.05%+24.38%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLUWBlue Water Acquisition Corp. III 1.00SellN/AN/AIZTCInvizyne Technologies 0.00N/AN/AN/AJATTJATT Acquisition 0.00N/AN/AN/APLXProtalix BioTherapeutics 3.00Buy$12.00503.02% UpsideCurrent Analyst Ratings BreakdownLatest BLUW, PLX, JATT, and IZTC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/24/2026BLUWBlue Water Acquisition Corp. III Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/10/2026BLUWBlue Water Acquisition Corp. III Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/19/2026PLXProtalix BioTherapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.00(Data available from 6/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLUWBlue Water Acquisition Corp. IIIN/AN/AN/AN/AN/AN/AIZTCInvizyne TechnologiesN/AN/AN/AN/AN/AN/AJATTJATT AcquisitionN/AN/A$0.38 per share27.08($0.53) per shareN/APLXProtalix BioTherapeutics$76.38M2.10$0.11 per share17.80$0.47 per share4.23Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLUWBlue Water Acquisition Corp. IIIN/AN/AN/AN/AN/AN/AN/AN/AN/AIZTCInvizyne TechnologiesN/AN/AN/AN/AN/AN/AN/AN/AN/AJATTJATT Acquisition$6.85MN/AN/AN/AN/AN/A-49.58%2.84%N/APLXProtalix BioTherapeutics$8.31M$0.18N/A6.42N/A-21.03%-30.89%-11.74%N/ALatest BLUW, PLX, JATT, and IZTC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026BLUWBlue Water Acquisition Corp. IIIN/A$0.08N/A$0.08N/AN/A4/14/2026Q4 2025BLUWBlue Water Acquisition Corp. IIIN/A-$0.03N/A-$0.03N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBLUWBlue Water Acquisition Corp. IIIN/AN/AN/AN/AN/AIZTCInvizyne TechnologiesN/AN/AN/AN/AN/AJATTJATT AcquisitionN/AN/AN/AN/AN/APLXProtalix BioTherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLUWBlue Water Acquisition Corp. IIIN/AN/AN/AIZTCInvizyne TechnologiesN/AN/AN/AJATTJATT AcquisitionN/A0.150.15PLXProtalix BioTherapeuticsN/A1.981.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLUWBlue Water Acquisition Corp. IIIN/AIZTCInvizyne TechnologiesN/AJATTJATT Acquisition47.97%PLXProtalix BioTherapeutics16.53%Insider OwnershipCompanyInsider OwnershipBLUWBlue Water Acquisition Corp. IIIN/AIZTCInvizyne TechnologiesN/AJATTJATT Acquisition20.00%PLXProtalix BioTherapeutics6.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLUWBlue Water Acquisition Corp. III228.12 millionN/ANot OptionableIZTCInvizyne Technologies296.25 millionN/AN/AJATTJATT Acquisition38.03 million13.80 millionNot OptionablePLXProtalix BioTherapeutics20080.57 million69.00 millionOptionableBLUW, PLX, JATT, and IZTC HeadlinesRecent News About These CompaniesHead-To-Head Analysis: Protalix BioTherapeutics (NYSE:PLX) versus Genocea Biosciences (NASDAQ:GNCAQ)June 6 at 3:47 AM | americanbankingnews.comContrasting Protalix BioTherapeutics (NYSE:PLX) & Genocea Biosciences (NASDAQ:GNCAQ)May 27, 2026 | americanbankingnews.comProtalix BioTherapeutics, Inc. Q1 2026 Earnings Call SummaryMay 15, 2026 | finance.yahoo.comPLX: Chiesi Milestone ReceivedMay 14, 2026 | finance.yahoo.comProtalix BioTherapeutics, Inc. (AMEX:PLX) Q1 2026 Earnings Call TranscriptMay 14, 2026 | insidermonkey.comTranscript: Protalix BioTherapeutics Q1 2026 Earnings Conference CallMay 14, 2026 | uk.finance.yahoo.comProtalix BioTherapeutics Inc (PLX) Q1 2026 Earnings Call Highlights: Strong Financial Position ...May 14, 2026 | finance.yahoo.comProtalix BioTherapeutics, Inc. (PLX) Q1 2026 Earnings Call TranscriptMay 13, 2026 | seekingalpha.comProtalix BioTherapeutics Reports First Quarter 2026 Financial and Business ResultsMay 13, 2026 | prnewswire.comProtalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026May 6, 2026 | prnewswire.comProtalix: Elfabrio Struggles Against Oral CompetitionApril 15, 2026 | seekingalpha.comProtalix Revenue Miss Overshadowed By Milestone-Backed 2026 GuidanceMarch 24, 2026 | seekingalpha.comProtalix BioTherapeutics, Inc.: Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business ResultsMarch 18, 2026 | finanznachrichten.deProtalix targets $78M–$83M 2026 revenue with EU milestone, advancing PRX-115March 18, 2026 | seekingalpha.comProtalix BioTherapeutics advances Fabry disease and gout programs during 2025March 18, 2026 | proactiveinvestors.comProtalix: Q4 Earnings SnapshotMarch 18, 2026 | finance.yahoo.comProtalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business ResultsMarch 18, 2026 | finance.yahoo.comProtalix BioTherapeutics and partner secure EU approval for new Fabry disease dosing regimenMarch 9, 2026 | proactiveinvestors.comChiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase ...March 9, 2026 | tmcnet.comChiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa)March 9, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBLUW, PLX, JATT, and IZTC Company DescriptionsBlue Water Acquisition Corp. III NASDAQ:BLUW$10.32 0.00 (0.00%) As of 06/5/2026 04:00 PM Eastern This is a fair market value price provided by Massive. Learn more.Blue Water Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in Greenwich, Connecticut.Invizyne Technologies NASDAQ:IZTC$9.34 -0.01 (-0.11%) As of 06/5/2026Invizyne Technologies Inc. is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc. is based in Monrovia, CA.JATT Acquisition NYSE:JATT$10.36 -0.11 (-1.00%) As of 06/5/2026 03:54 PM Eastern This is a fair market value price provided by Massive. Learn more.JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.Protalix BioTherapeutics NYSE:PLX$1.99 -0.02 (-1.00%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$1.98 -0.01 (-0.50%) As of 06/5/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/01 - 06/05 Samsara Just Answered The AI Question—Is Wall Street Ready To Listen? A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? IREN's 800MW Bet Flips the AI Power Switch Buy the Dip? Broadcom's AI Moat Is Wider Than Ever CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip? The Market Has Ollie’s Bargain Outlet Completely Wrong Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
